Clinical Trial Update: YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing YL202 to physician's choice in HR+/HER2- locally advanced or metastatic breast cancer; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• YL202

Snippet

Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. | Conditions: Locally Advanced or Metastatic Breast Cancer | Phase 3 | Status: NOT_YET_RECRUITING